Literature DB >> 16973753

Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis.

Miao Wang1, Alicia M Zukas, Yiqun Hui, Emanuela Ricciotti, Ellen Puré, Garret A FitzGerald.   

Abstract

Prostaglandin (PG) E(2) is formed from PGH(2) by a series of PGE synthase (PGES) enzymes. Microsomal PGES-1(-/-) (mPGES-1(-/-)) mice were crossed into low-density lipoprotein receptor knockout (LDLR(-/-)) mice to generate mPGES-1(-/-) LDLR(-/-)s. Urinary 11alpha-hydroxy-9, 15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic acid (PGE-M) was depressed by mPGES-1 deletion. Vascular mPGES-1 was augmented during atherogenesis in LDLR(-/-)s. Deletion of mPGES-1 reduced plaque burden in fat-fed LDLR(-/-)s but did not alter blood pressure. mPGES-1(-/-) LDLR(-/-) plaques were enriched with fibrillar collagens relative to LDLR(-/-), which also contained small and intermediate-sized collagens. Macrophage foam cells were depleted in mPGES-1(-/-) LDLR(-/-) lesions, whereas the total areas rich in vascular smooth muscle cell (VSMC) and matrix were unaltered. mPGES-1 deletion augmented expression of both prostacyclin (PGI(2)) and thromboxane (Tx) synthases in endothelial cells, and VSMCs expressing PGI synthase were enriched in mPGES-1(-/-) LDLR(-/-) lesions. Stimulation of mPGES-1(-/-) VSMC and macrophages with bacterial LPS increased PGI(2) and thromboxane A(2) to varied extents. Urinary PGE-M was depressed, whereas urinary 2,3-dinor 6-keto PGF(1alpha), but not 2,3-dinor-TxB(2), was increased in mPGES-1(-/-) LDLR(-/-)s. mPGES-1-derived PGE(2) accelerates atherogenesis in LDLR(-/-) mice. Disruption of this enzyme retards atherogenesis, without an attendant impact on blood pressure. This may reflect, in part, rediversion of accumulated PGH(2) to augment formation of PGI(2). Inhibitors of mPGES-1 may be less likely than those selective for cyclooxygenase 2 to result in cardiovascular complications because of a divergent impact on the biosynthesis of PGI(2).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16973753      PMCID: PMC1566188          DOI: 10.1073/pnas.0606586103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  High glucose via peroxynitrite causes tyrosine nitration and inactivation of prostacyclin synthase that is associated with thromboxane/prostaglandin H(2) receptor-mediated apoptosis and adhesion molecule expression in cultured human aortic endothelial cells.

Authors:  Ming-Hui Zou; Chaomei Shi; Richard A Cohen
Journal:  Diabetes       Date:  2002-01       Impact factor: 9.461

2.  Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation.

Authors:  J E Fabre; M Nguyen; K Athirakul; K Coggins; J D McNeish; S Austin; L K Parise; G A FitzGerald; T M Coffman; B H Koller
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

3.  Human microsomal prostaglandin E synthase-1: purification, functional characterization, and projection structure determination.

Authors:  Staffan Thorén; Rolf Weinander; Sipra Saha; Caroline Jegerschöld; Pär L Pettersson; Bengt Samuelsson; Hans Hebert; Mats Hamberg; Ralf Morgenstern; Per-Johan Jakobsson
Journal:  J Biol Chem       Date:  2003-04-02       Impact factor: 5.157

Review 4.  Prostaglandins and leukotrienes: advances in eicosanoid biology.

Authors:  C D Funk
Journal:  Science       Date:  2001-11-30       Impact factor: 47.728

5.  Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries.

Authors:  J K Hennan; J Huang; T D Barrett; E M Driscoll; D E Willens; A M Park; L J Crofford; B R Lucchesi
Journal:  Circulation       Date:  2001-08-14       Impact factor: 29.690

6.  Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice.

Authors:  Michael E Burleigh; Vladimir R Babaev; John A Oates; Raymond C Harris; Shiva Gautam; Denis Riendeau; Lawrence J Marnett; Jason D Morrow; Sergio Fazio; MacRae F Linton
Journal:  Circulation       Date:  2002-04-16       Impact factor: 29.690

7.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors:  C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal:  N Engl J Med       Date:  2000-11-23       Impact factor: 91.245

8.  Role of prostacyclin in the cardiovascular response to thromboxane A2.

Authors:  Yan Cheng; Sandra C Austin; Bianca Rocca; Beverly H Koller; Thomas M Coffman; Tilo Grosser; John A Lawson; Garret A FitzGerald
Journal:  Science       Date:  2002-04-19       Impact factor: 47.728

9.  Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase.

Authors:  Catherine E Trebino; Jeffrey L Stock; Colleen P Gibbons; Brian M Naiman; Timothy S Wachtmann; John P Umland; Karamjeet Pandher; Jean-Martin Lapointe; Sipra Saha; Marsha L Roach; Demetrius Carter; Nathalie A Thomas; Becky A Durtschi; John D McNeish; John E Hambor; Per-Johan Jakobsson; Thomas J Carty; Jose R Perez; Laurent P Audoly
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-30       Impact factor: 11.205

10.  Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor.

Authors:  Kiyoshi Takayama; Guillermo García-Cardena; Galina K Sukhova; Jason Comander; Michael A Gimbrone; Peter Libby
Journal:  J Biol Chem       Date:  2002-09-04       Impact factor: 5.157

View more
  66 in total

1.  Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1.

Authors:  Jenny E Kanter; Farah Kramer; Shelley Barnhart; Michelle M Averill; Anuradha Vivekanandan-Giri; Thad Vickery; Lei O Li; Lev Becker; Wei Yuan; Alan Chait; Kathleen R Braun; Susan Potter-Perigo; Srinath Sanda; Thomas N Wight; Subramaniam Pennathur; Charles N Serhan; Jay W Heinecke; Rosalind A Coleman; Karin E Bornfeldt
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

2.  Potential roles of microsomal prostaglandin E synthase-1 in rheumatoid arthritis.

Authors:  Fumiaki Kojima; Rahul G Matnani; Shinichi Kawai; Fumitaka Ushikubi; Leslie J Crofford
Journal:  Inflamm Regen       Date:  2011-03

Review 3.  PGE2, Kidney Disease, and Cardiovascular Risk: Beyond Hypertension and Diabetes.

Authors:  Rania Nasrallah; Ramzi Hassouneh; Richard L Hébert
Journal:  J Am Soc Nephrol       Date:  2015-08-28       Impact factor: 10.121

4.  Microsomal prostaglandin e2 synthase-1 modulates the response to vascular injury.

Authors:  Miao Wang; Kaori Ihida-Stansbury; Devashish Kothapalli; Mathieu C Tamby; Zhou Yu; Lihong Chen; Gregory Grant; Yan Cheng; John A Lawson; Richard K Assoian; Peter L Jones; Garret A Fitzgerald
Journal:  Circulation       Date:  2011-01-31       Impact factor: 29.690

5.  Cyclooxygenase products and atherosclerosis.

Authors:  Macrae F Linton; Sergio Fazio
Journal:  Drug Discov Today Ther Strateg       Date:  2008

6.  Reduced T cell-dependent humoral immune response in microsomal prostaglandin E synthase-1 null mice is mediated by nonhematopoietic cells.

Authors:  Fumiaki Kojima; Andrey Frolov; Rahul Matnani; Jerold G Woodward; Leslie J Crofford
Journal:  J Immunol       Date:  2013-10-14       Impact factor: 5.422

7.  Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis.

Authors:  Hiroyasu Sato; Rina Kato; Yuki Isogai; Go-ichi Saka; Mitsuhiro Ohtsuki; Yoshitaka Taketomi; Kei Yamamoto; Kae Tsutsumi; Joe Yamada; Seiko Masuda; Yukio Ishikawa; Toshiharu Ishii; Tetsuyuki Kobayashi; Kazutaka Ikeda; Ryo Taguchi; Shinji Hatakeyama; Shuntaro Hara; Ichiro Kudo; Hiroyuki Itabe; Makoto Murakami
Journal:  J Biol Chem       Date:  2008-09-18       Impact factor: 5.157

8.  Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injury.

Authors:  Keiichi Hishikari; Jun-ichi Suzuki; Masahito Ogawa; Kazuya Isobe; Teisuke Takahashi; Michihito Onishi; Kiyoshi Takayama; Mitsuaki Isobe
Journal:  Cardiovasc Res       Date:  2008-09-18       Impact factor: 10.787

9.  Dose-dependent acute liver injury with hypersensitivity features in humans due to a novel microsomal prostaglandin E synthase 1 inhibitor.

Authors:  Yan Jin; Arie Regev; Jeanelle Kam; Krista Phipps; Claire Smith; Judith Henck; Kristina Campanale; Leijun Hu; D Greg Hall; Xiao Yan Yang; Masako Nakano; Terry Ann McNearney; Jack Uetrecht; William Landschulz
Journal:  Br J Clin Pharmacol       Date:  2017-10-08       Impact factor: 4.335

10.  Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer.

Authors:  Patrick G Morris; Xi Kathy Zhou; Ginger L Milne; Daniel Goldstein; Laura C Hawks; Chau T Dang; Shanu Modi; Monica N Fornier; Clifford A Hudis; Andrew J Dannenberg
Journal:  Cancer Prev Res (Phila)       Date:  2013-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.